Synthetic biology is a transformative set of technologies which offer great opportunities for the construction of bioengineered parts, devices and microorganisms.
English, , 2,570kb
The 2009 edition brings together the latest available economic and activity data on biotechnology and innovation for 22 OECD members and four non-member countries. It builds on the extensive work of the OECD and national experts to improve the comparability of biotechnology statistics.
The impact of biotechnologies on medical research is intensifying. Because of new highly performing technologies, we are better able to understand and explore disease and drug mechanisms, which in turn could lead to major changes in the approach of patient care.
The focus at the OECD on industrial biotechnology is to identify the potential contribution of biotechnology to sustainable growth and development, and identify and appraise policy options for supply and demand side interventions that can drive efficient transition towards bio-based economy.
Genetics is playing an increasingly important role in health care. New technical advances and information deriving from human genome research are changing health care practices and the economics of healthcare provision.
This report presents the outcome of discussions held by the OECD member countries, together with a number of key partner countries, under the auspices of an expert Task Force established by the OECD Working Party on Biotechnology.
Summarises proceedings of a conference looking at examples of human genetic research databases, how they are established, how they are managed and governed, how they might be commercialised, and what the policy considerations might be.
English, , 849kb
The 2006 edition OECD Biotechnology Statistics includes data for 23 OECD countries and two observer countries, plus China (Shanghai), and takes a major step forward in improving the comparability of biotechnology indicators among countries.
This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries. Based on rich evidence, it draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.
These guidelines offer principles and best practices for the licensing of genetic inventions used for the purpose of human health care.